[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633341":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":52,"centralContacts":56,"locations":63,"responsibleParty":297,"collaborators":299,"id":303,"slug":38,"hasResults":304,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":38,"eligibilityCriteria":308,"healthyVolunteers":304,"sex":309,"minAge":310,"maxAge":311,"enrollmentInfo":312,"targetDuration":38,"studyType":315,"phases":316,"briefSummary":318,"conditions":319,"keywords":321,"overallStatus":66,"whyStopped":38,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":337},{"fullName":5,"class":6},"Gates Medical Research Institute","OTHER",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1","EXPERIMENTAL","The combination of TBD09 (100 mg three times weekly, TIW), bedaquiline and pretomanid",[13],"Drug: Bedaquiline, pretomanid and TBD09",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2","The combination of TBD09 (100 mg QD), bedaquiline and pretomanid",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group 3","The combination of TBD09 (300 mg QD), bedaquiline and pretomanid",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Group 4","The combination of TBD09 (500 mg QD), bedaquiline and pretomanid",[13],{"label":27,"type":28,"description":29,"interventionNames":30},"Group 5","ACTIVE_COMPARATOR","The combination of linezolid (600 mg QD), bedaquiline and pretomanid",[31],"Drug: Bedaquiline, pretomanid and linezolid",[33,39,42,45,48],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","Bedaquiline, pretomanid and TBD09","Group 1 (30 participants): The combination of TBD09 (100 mg three times weekly, TIW), bedaquiline (200 mg daily, QD), and pretomanid (200 mg QD), 28 days",[9],null,{"type":34,"name":35,"description":40,"armGroupLabels":41,"otherNames":38},"Group 2 (30 participants): The combination of TBD09 (100 mg QD), bedaquiline (200 mg QD), and pretomanid (200 mg QD), 28 days",[15],{"type":34,"name":35,"description":43,"armGroupLabels":44,"otherNames":38},"Group 3 (30 participants): The combination of TBD09 (300 mg QD), bedaquiline (200 mg QD), and pretomanid (200 mg QD), 28 days",[19],{"type":34,"name":35,"description":46,"armGroupLabels":47,"otherNames":38},"Group 4 (30 participants): The combination of TBD09 (500 mg QD), bedaquiline (200 mg QD), and pretomanid (200 mg QD), 28 days",[23],{"type":34,"name":49,"description":50,"armGroupLabels":51,"otherNames":38},"Bedaquiline, pretomanid and linezolid","Group 5 (30 participants): The combination of linezolid (600 mg QD), bedaquiline (200 mg QD), and pretomanid (200 mg QD), 28 days",[27],[53],{"name":54,"affiliation":5,"role":55},"Gates MRI","STUDY_DIRECTOR",[57,61],{"name":54,"role":58,"phone":59,"phoneExt":38,"email":60},"CONTACT","+1 857 702 2108","clinical.trials@gatesmri.org",{"name":54,"role":58,"phone":62,"phoneExt":38,"email":38},"+1-866-789-5757",[64,87,106,125,144,163,182,201,220,234,249,264,279],{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Enhancing Care Foundation at Wentworth Hospital","RECRUITING","Durban","Bluff","4052","South Africa",{"type":72,"coordinates":73},"Point",[74,75],31.0292,-29.8579,{"lat":75,"lon":74},[78,82,85],{"name":79,"role":58,"phone":80,"phoneExt":38,"email":81},"Sundrapragasen (Sandy) Pillay, MD","+27 31 4611629","pillay@ecarefoundation.com",{"name":83,"role":58,"phone":38,"phoneExt":38,"email":84},"Penelope Madlala","pmadlala@ecarefoundation.com",{"name":79,"role":86,"phone":38,"phoneExt":38,"email":38},"PRINCIPAL_INVESTIGATOR",{"facility":88,"status":66,"city":89,"state":90,"zip":91,"country":70,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"TASK Applied Science - Eden","George","Central","6529",{"type":72,"coordinates":93},[94,95],22.46173,-33.963,{"lat":95,"lon":94},[98,102,105],{"name":99,"role":58,"phone":100,"phoneExt":38,"email":101},"Suzanne Staples, MD","044 873 3395","s.staples@taskclinical.com",{"name":103,"role":58,"phone":38,"phoneExt":38,"email":104},"Amkelwa Dlunge","a.dlunge@taskclinical.com",{"name":99,"role":86,"phone":38,"phoneExt":38,"email":38},{"facility":107,"status":66,"city":108,"state":109,"zip":110,"country":70,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Clinical Research and HIV Research Unit (CHRU) @ Helen Joseph Hospital","Johannesburg","Gauteng","2092",{"type":72,"coordinates":112},[113,114],28.04363,-26.20227,{"lat":114,"lon":113},[117,121,124],{"name":118,"role":58,"phone":119,"phoneExt":38,"email":120},"Mohammed Rassool, MD","112768800","mrassool@witshealth.co.za",{"name":122,"role":58,"phone":38,"phoneExt":38,"email":123},"Betty Matome","bmatome@witshealth.co.za",{"name":118,"role":86,"phone":38,"phoneExt":38,"email":38},{"facility":126,"status":127,"city":128,"state":109,"zip":129,"country":70,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"The Aurum Institute Tembisa","NOT_YET_RECRUITING","Tembisa","1736",{"type":72,"coordinates":131},[132,133],28.22762,-26.00979,{"lat":133,"lon":132},[136,140,143],{"name":137,"role":58,"phone":138,"phoneExt":38,"email":139},"Mmatsie Manentsa, MD","27828214157","mmanentsa@auruminstitute.org",{"name":141,"role":58,"phone":38,"phoneExt":38,"email":142},"Tebatso Matsepe","tmatsepe@auruminstitute.org",{"name":137,"role":86,"phone":38,"phoneExt":38,"email":38},{"facility":145,"status":66,"city":146,"state":147,"zip":148,"country":70,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"CHRU @ Isango Lethemba","Bethelsdorp","Gqeberha","6003",{"type":72,"coordinates":150},[151,152],25.51242,-33.88856,{"lat":152,"lon":151},[155,159,162],{"name":156,"role":58,"phone":157,"phoneExt":38,"email":158},"Simone Faesen, MD","27 41 811 0347","Simfaesen@witshealth.co.za",{"name":160,"role":58,"phone":38,"phoneExt":38,"email":161},"Thuso Malatsi","Tmalatsi@witshealth.co.za",{"name":156,"role":86,"phone":38,"phoneExt":38,"email":38},{"facility":164,"status":66,"city":165,"state":166,"zip":167,"country":70,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"Madibeng Centre for Research","Brits","North West","0250",{"type":72,"coordinates":169},[170,171],27.78022,-25.63473,{"lat":171,"lon":170},[174,178,181],{"name":175,"role":58,"phone":176,"phoneExt":38,"email":177},"Lindsey Faul, MD","+27 12 252 1140","lfaul@madibengresearch.co.za",{"name":179,"role":58,"phone":38,"phoneExt":38,"email":180},"Ralinah Maepa","rmaepa@madibengresearch.co.za",{"name":175,"role":86,"phone":38,"phoneExt":38,"email":38},{"facility":183,"status":66,"city":184,"state":185,"zip":186,"country":70,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Setshaba Research Center","Pretoria","Soshangue","0152",{"type":72,"coordinates":188},[189,190],28.18783,-25.74486,{"lat":190,"lon":189},[193,197,200],{"name":194,"role":58,"phone":195,"phoneExt":38,"email":196},"Ntokozo Zuma-Gwala, MD","073 476 1398","NZuma-Gwala@setshaba.org.za",{"name":198,"role":58,"phone":38,"phoneExt":38,"email":199},"Mohammed Osman","mosman@setshaba.org.za",{"name":194,"role":86,"phone":38,"phoneExt":38,"email":38},{"facility":202,"status":66,"city":203,"state":204,"zip":205,"country":70,"cosmosGeoPoint":206,"geoPoint":210,"contacts":211},"ONE MRI","Cape Town","Western Cape","7405",{"type":72,"coordinates":207},[208,209],18.42322,-33.92584,{"lat":209,"lon":208},[212,216,219],{"name":213,"role":58,"phone":214,"phoneExt":38,"email":215},"Sandra Mukasa, MD","064 016 2837","sandra.mukasa@onemri.co.za",{"name":217,"role":58,"phone":38,"phoneExt":38,"email":218},"Nosipho Mkuzangwe","nosie.mkuzangwe@uct.ac.za",{"name":213,"role":86,"phone":38,"phoneExt":38,"email":38},{"facility":221,"status":66,"city":203,"state":204,"zip":205,"country":70,"cosmosGeoPoint":222,"geoPoint":224,"contacts":225},"TASK Applied Science - Brookylyn Chest Hospital",{"type":72,"coordinates":223},[208,209],{"lat":209,"lon":208},[226,230,233],{"name":227,"role":58,"phone":228,"phoneExt":38,"email":229},"Fairoez Ryklief, MD","021 510 2209","dr.fairoez@task.org.za",{"name":231,"role":58,"phone":38,"phoneExt":38,"email":232},"Khomotso Zitha","k.zitha@taskclinical.com",{"name":227,"role":86,"phone":38,"phoneExt":38,"email":38},{"facility":235,"status":66,"city":203,"state":204,"zip":236,"country":70,"cosmosGeoPoint":237,"geoPoint":239,"contacts":240},"BioMedical Research Institute - Stellenbosch University @ Tygerberg Hospital","7505",{"type":72,"coordinates":238},[208,209],{"lat":209,"lon":208},[241,245,248],{"name":242,"role":58,"phone":243,"phoneExt":38,"email":244},"Andriette Hiemstra, MD","021 938 9639","ahiemstra@sun.ac.za",{"name":246,"role":58,"phone":38,"phoneExt":38,"email":247},"Bernadine Fransman","bfransman@sun.ac.za",{"name":242,"role":86,"phone":38,"phoneExt":38,"email":38},{"facility":250,"status":66,"city":203,"state":204,"zip":251,"country":70,"cosmosGeoPoint":252,"geoPoint":254,"contacts":255},"UCT Lung Institute","7700",{"type":72,"coordinates":253},[208,209],{"lat":209,"lon":208},[256,260,263],{"name":257,"role":58,"phone":258,"phoneExt":38,"email":259},"Rodney Dawson, MD","27214067976","rodney.dawson@uct.ac.za",{"name":261,"role":58,"phone":38,"phoneExt":38,"email":262},"Shanice Johnson","shanice.johnson@uct.ac.za",{"name":257,"role":86,"phone":38,"phoneExt":38,"email":38},{"facility":265,"status":127,"city":203,"state":204,"zip":266,"country":70,"cosmosGeoPoint":267,"geoPoint":269,"contacts":270},"Desmond Tutu Health Foundation","7750",{"type":72,"coordinates":268},[208,209],{"lat":209,"lon":208},[271,275,278],{"name":272,"role":58,"phone":273,"phoneExt":38,"email":274},"Keren Middelkoop, MD","717999262","Keren.Middelkoop@hiv-research.org.za",{"name":276,"role":58,"phone":38,"phoneExt":38,"email":277},"Jabulisile Zuma","Jabulisile.Zuma@hiv-research.org.za",{"name":272,"role":86,"phone":38,"phoneExt":38,"email":38},{"facility":280,"status":66,"city":281,"state":38,"zip":282,"country":70,"cosmosGeoPoint":283,"geoPoint":287,"contacts":288},"Synergy Biomedical Research Institute (SBRI)","East London","5241",{"type":72,"coordinates":284},[285,286],27.91162,-33.01529,{"lat":286,"lon":285},[289,293,296],{"name":290,"role":58,"phone":291,"phoneExt":38,"email":292},"Mookho Malahleha, MD","437222306","drmookho@sbri.org.za",{"name":294,"role":58,"phone":38,"phoneExt":38,"email":295},"Nqobile Msweli","nqobile@sbri.org.za",{"name":290,"role":86,"phone":38,"phoneExt":38,"email":38},{"type":298,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR",[300],{"name":301,"class":302},"IQVIA RDS Inc.","INDUSTRY","100633341",false,"NCT07525427","Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis","A Phase 2, Open-Label, Multi-Group, Controlled, Randomized Trial of the Safety, Bactericidal Activity, and Pharmacokinetics of TBD09 in Combination With Other Active Agents in Adults With Drug-Sensitive Pulmonary Tuberculosis","Inclusion Criteria:\n\n* Age 18-65 years at consent\n* Body weight 35-100 kg at screening\n* Written informed consent obtained\n* Newly diagnosed rifampicin-sensitive pulmonary TB\n\n  * Molecular confirmation of M. tuberculosis on Xpert MTB\u002FRIF Ultra\n  * ≥1+ AFB smear or Xpert Ultra low, medium, or high semi-quantitative result\n  * Rifampicin sensitivity on molecular test\n* Chest X-ray consistent with TB (Investigator assessment)\n* Able to spontaneously produce sputum\n* Reproductive requirements met\n* Women of childbearing potential: 2 approved contraceptive methods or abstinence\n* Males: contraception or abstinence through 90 days post-dose\n\nExclusion Criteria:\n\n* Prior anti-TB treatment for the current TB episode within 60 days\n* Prior medication active against Mtb within 3 months\n* Evidence of extra-thoracic TB, per investigator judgement\n* Prior treatment completion for TB within 3 years\n* 2 or more prior episodes of TB\n* Clinically significant history of or current medical condition posing safety risk\n* If HIV positive:\n\n  * Not on ARVs or taking ARVs for \\\u003C3 months prior to screening OR\n  * CD4+ count \\\u003C200cells\u002FuL at screening OR\n  * HIV viral load \\>200 copies \u002FmL at screening OR\n  * AIDS infection or malignancies\n* Meets any of the following laboratory values during screening:\n\n  * AST, ALT, or ALP ≥2.5× ULN\n  * Total bilirubin ≥1.2× ULN\n  * eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m²\n  * Hemoglobin \\\u003C9.0 g\u002FdL (male) or \\\u003C8.5 g\u002FdL (female)\n  * White blood cell count \\\u003C2,000\u002Fmm³\n  * Absolute neutrophil count \\\u003C800\u002Fmm³\n  * Platelet count ≤100,000\u002Fmm³\n  * Positive hepatitis B surface antigen\n  * Positive hepatitis C antibody\n  * HbA1c ≥8.0%\n* Current or recent systemic immunosuppressive therapy, including corticosteroids\n* Significant drug or alcohol abuse affecting compliance or safety\n* Pregnant or breastfeeding, positive pregnancy test, or planning pregnancy shortly after treatment","ALL","18 Years","65 Years",{"count":313,"type":314},150,"ESTIMATED","INTERVENTIONAL",[317],"PHASE2","The purpose of this study is to evaluate if TBD09 in combination with other active agents in adults with drug sensitive pulmonary tuberculosis has potential to be safe and effective.",[320],"Drug Susceptible Pulmonary Tuberculosis",[322,323,324,325,326,327],"TBD09","oxazolidinone","bedaquiline","pretomanid","linezolid","drug-susceptible pulmonary tuberculosis","2026-06-01",{"date":330,"type":331},"2026-06-03","ACTUAL",{"date":333,"type":331},"2026-04-14",{"date":335,"type":314},"2026-11-05",{"name":5,"class":6},13]